<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK447152" /><meta name="ncbi_domain" content="gene" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK447152/" /><meta name="ncbi_pagename" content="Complete Plasminogen Activator Inhibitor 1 Deficiency - GeneReviews® - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Complete Plasminogen Activator Inhibitor 1 Deficiency - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="GeneReviews® [Internet]" /><meta name="citation_title" content="Complete Plasminogen Activator Inhibitor 1 Deficiency" /><meta name="citation_publisher" content="University of Washington, Seattle" /><meta name="citation_date" content="2017/08/03" /><meta name="citation_author" content="Meadow Heiman" /><meta name="citation_author" content="Sweta Gupta" /><meta name="citation_author" content="Sadiya S Khan" /><meta name="citation_author" content="Douglas E Vaughan" /><meta name="citation_author" content="Amy D Shapiro" /><meta name="citation_pmid" content="28771291" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK447152/" /><meta name="citation_keywords" content="Complete PAI-1 Deficiency" /><meta name="citation_keywords" content="Homozygous PAI-1 Deficiency" /><meta name="citation_keywords" content="Complete PAI-1 Deficiency" /><meta name="citation_keywords" content="Homozygous PAI-1 Deficiency" /><meta name="citation_keywords" content="Plasminogen activator inhibitor 1" /><meta name="citation_keywords" content="SERPINE1" /><meta name="citation_keywords" content="Complete Plasminogen Activator Inhibitor 1 Deficiency" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Complete Plasminogen Activator Inhibitor 1 Deficiency" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="University of Washington, Seattle" /><meta name="DC.Contributor" content="Meadow Heiman" /><meta name="DC.Contributor" content="Sweta Gupta" /><meta name="DC.Contributor" content="Sadiya S Khan" /><meta name="DC.Contributor" content="Douglas E Vaughan" /><meta name="DC.Contributor" content="Amy D Shapiro" /><meta name="DC.Date" content="2017/08/03" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK447152/" /><meta name="description" content="Untreated complete plasminogen activator inhibitor 1 (PAI-1) deficiency is characterized by mild to moderate bleeding, although in some instances bleeding can be life threatening. Most commonly, delayed bleeding is associated with injury, trauma, or surgery; spontaneous bleeding does not occur. While males and females with complete PAI-1 deficiency are affected equally, females may present more frequently with clinical manifestations or earlier in life than males due to menorrhagia and postpartum hemorrhage. Fewer than ten families with complete PAI-1 deficiency have been reported to date. The incidence of complete PAI-1 deficiency is higher than expected in the genetic isolate of the Old Order Amish population of eastern and southern Indiana due to a pathogenic founder variant. In one family from this Old Order Amish population, seven individuals had cardiac fibrosis ranging from minimal-to-moderate (6 individuals) to severe (1)." /><meta name="og:title" content="Complete Plasminogen Activator Inhibitor 1 Deficiency" /><meta name="og:type" content="book" /><meta name="og:description" content="Untreated complete plasminogen activator inhibitor 1 (PAI-1) deficiency is characterized by mild to moderate bleeding, although in some instances bleeding can be life threatening. Most commonly, delayed bleeding is associated with injury, trauma, or surgery; spontaneous bleeding does not occur. While males and females with complete PAI-1 deficiency are affected equally, females may present more frequently with clinical manifestations or earlier in life than males due to menorrhagia and postpartum hemorrhage. Fewer than ten families with complete PAI-1 deficiency have been reported to date. The incidence of complete PAI-1 deficiency is higher than expected in the genetic isolate of the Old Order Amish population of eastern and southern Indiana due to a pathogenic founder variant. In one family from this Old Order Amish population, seven individuals had cardiac fibrosis ranging from minimal-to-moderate (6 individuals) to severe (1)." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK447152/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/gene/pai-1-def/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK447152/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE8AF0AFDFC8A2710000000003DA01F7.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All GeneReviews" href="/books/n/gene/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" alt="Cover of GeneReviews®" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>GeneReviews<sup>®</sup> [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK447152_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK447152_dtls__"><div>Adam MP, Ardinger HH, Pagon RA, et al., editors.</div><div>Seattle (WA): <a href="http://www.washington.edu" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">University of Washington, Seattle</a>; 1993-2019.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/gene/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search GeneReviews" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search GeneReviews" submit="false" style="padding: 0.1em 0.4em;" /></div></form><div><ul class="inline_list"><li><a href="/books/n/gene/advanced/">GeneReviews Advanced Search</a></li><li style="margin-left:.5em"><a href="/books/n/gene/helpadvsearch/">Help</a></li></ul></div></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/bethlem/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/ccfdn/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK447152_"><span class="title" itemprop="name">Complete Plasminogen Activator Inhibitor 1 Deficiency</span></h1><div itemprop="alternativeHeadline" class="subtitle whole_rhythm">Synonyms: Complete PAI-1 Deficiency, Homozygous PAI-1 Deficiency</div><p class="contrib-group"><span itemprop="author">Meadow Heiman</span>, MS, <span itemprop="author">Sweta Gupta</span>, MD, <span itemprop="author">Sadiya S Khan</span>, MD, <span itemprop="author">Douglas E Vaughan</span>, MD, and <span itemprop="author">Amy D Shapiro</span>, MD.</p><a data-jig="ncbitoggler" href="#__NBK447152_ai__" style="border:0;text-decoration:none">Author Information</a><div style="display:none" class="ui-widget" id="__NBK447152_ai__"><div class="contrib half_rhythm"><span itemprop="author">Meadow Heiman</span>, MS<div class="affiliation small">Indiana Hemophilia &#x00026; Thrombosis Center<br />Indianapolis, Indiana<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="gro.CTHI@namiehm" class="oemail">gro.CTHI@namiehm</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Sweta Gupta</span>, MD<div class="affiliation small">Indiana Hemophilia &#x00026; Thrombosis Center<br />Indianapolis, Indiana<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="gro.cthi@atpugs" class="oemail">gro.cthi@atpugs</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Sadiya S Khan</span>, MD<div class="affiliation small">Northwestern University Feinberg School of Medicine<br />Chicago, Illinois<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.nretsewhtron@1-nahk-s" class="oemail">ude.nretsewhtron@1-nahk-s</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Douglas E Vaughan</span>, MD<div class="affiliation small">Northwestern University Feinberg School of Medicine<br />Chicago, Illinois<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ude.nretsewhtron@nahguav-d" class="oemail">ude.nretsewhtron@nahguav-d</a></div></div></div><div class="contrib half_rhythm"><span itemprop="author">Amy D Shapiro</span>, MD<div class="affiliation small">Indiana Hemophilia &#x00026; Thrombosis Center<br />Indianapolis, Indiana<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="gro.cthi@oripahsa" class="oemail">gro.cthi@oripahsa</a></div></div></div></div><p class="small">Initial Posting: <span itemprop="datePublished">August 3, 2017</span>.</p><p><em>Estimated reading time: 20 minutes</em></p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="pai-1-def.Summary" itemprop="description"><h2 id="_pai-1-def_Summary_">Summary</h2><div><h4 class="inline">Clinical characteristics.</h4><p>Untreated complete plasminogen activator inhibitor 1 (PAI-1) deficiency is characterized by mild to moderate bleeding, although in some instances bleeding can be life threatening. Most commonly, delayed bleeding is associated with injury, trauma, or surgery; spontaneous bleeding does not occur. While males and females with complete PAI-1 deficiency are <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> equally, females may present more frequently with clinical manifestations or earlier in life than males due to menorrhagia and postpartum hemorrhage. Fewer than ten families with complete PAI-1 deficiency have been reported to date. The incidence of complete PAI-1 deficiency is higher than expected in the genetic isolate of the Old Order Amish population of eastern and southern Indiana due to a pathogenic <a class="def" href="/books/n/gene/glossary/def-item/founder-variant/">founder variant</a>. In one family from this Old Order Amish population, seven individuals had cardiac fibrosis ranging from minimal-to-moderate (6 individuals) to severe (1).</p></div><div><h4 class="inline">Diagnosis/testing.</h4><p>The diagnosis of complete PAI-1 deficiency is established in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> when PAI-1 antigen is undetectable and PAI-1 activity is lower than 1 IU/mL<sup>-1</sup> and/or <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> <i>SERPINE1</i> pathogenic variants are identified on <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a>. Note that because the normal range of functional PAI-1 activity assay starts at zero in most laboratories, the ability to discriminate between normal and abnormal levels of activity is limited.</p></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations:</i> Management of the bleeding disorder by a team of experts in the treatment of individuals with bleeding disorders is highly recommended. Intravenous antifibrinolytics (e.g., epsilon-aminocaproic acid [EACA] and tranexamic acid) can be used for severe bleeding manifestations, including intracranial hemorrhage (with or without hematoma evacuation). Infusion of fresh-frozen plasma can be used as needed to increase PAI-1 activity prior to achieving therapeutic steady state levels of antifibrinolytics. Heavy menstrual bleeding can often be managed with antifibrinolytics or hormonal suppression therapy. Treatment of cardiac fibrosis is symptomatic.</p><p><i>Prevention of primary manifestations:</i> Antifibrinolytics should be used to prevent bleeding for surgical and dental procedures, childbirth, and other invasive procedures.</p><p><i>Surveillance:</i> Regular follow up with a team of experts in the treatment of individuals with bleeding disorders is recommended. For all individuals with complete PAI-1 deficiency, screening echocardiogram for evidence of cardiac fibrosis is recommended beginning at age 15 years with follow up for those with positive findings as indicated by a cardiologist and every two years for those with no cardiac findings at the time of the last screening.</p><p><i>Agents/circumstances to avoid:</i> Medications that affect coagulation including aspirin, ibuprofen, and some herbal remedies; high-risk activities such as contact sports.</p><p><i>Evaluation of relatives at risk:</i> It is appropriate to clarify the genetic status of apparently asymptomatic older and younger sibs of an individual with complete PAI-1 deficiency in order to identify as early as possible those who would benefit from prompt initiation of treatment and preventive measures.</p><p><i>Pregnancy management:</i> Recommendations based on published findings during pregnancies in two women with complete PAI-1 deficiency are oral administration of either tranexamic acid or EACA for intermittent bleeding in the first and second trimester, from 26 weeks&#x02019; gestation through delivery, and for at least two weeks post partum. Note: Evidence that these recommendations would be effective in all pregnancies of women with complete PAI-1 deficiency is lacking; the teratogenicity of EACA and tranexamic acid is unknown and information regarding their safety during pregnancy and lactation is limited.</p></div><div><h4 class="inline">Genetic counseling.</h4><p>Complete PAI-1 deficiency is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner. Heterozygotes (carriers) are asymptomatic and are not at risk of developing complete PAI-1 deficiency. At conception, each sib of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual has a 25% chance of being affected, a 50% chance of being an asymptomatic <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>, and a 25% chance of being unaffected and not a carrier. Once the <i>SERPINE1</i> pathogenic variants have been identified in an affected family member, <a class="def" href="/books/n/gene/glossary/def-item/carrier-testing/">carrier testing</a> for at-risk relatives, prenatal testing for a pregnancy at increased risk for complete PAI-1 deficiency, and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> are possible.</p></div></div><div id="pai-1-def.Diagnosis"><h2 id="_pai-1-def_Diagnosis_">Diagnosis</h2><p>No formal diagnostic criteria for establishing a diagnosis of complete plasminogen activator inhibitor 1 (PAI-1) deficiency have been published.</p><div id="pai-1-def.Suggestive_Findings"><h3>Suggestive Findings</h3><p>Complete PAI-1 deficiency <b>should be suspected</b> in individuals with the following <a href="#pai-1-def.Medical_History">medical history</a> and <a href="#pai-1-def.Laboratory_Findings">laboratory findings</a>.</p><div id="pai-1-def.Medical_History"><h4>Medical History</h4><p>Bleeding disorder that typically presents as:</p><ul><li class="half_rhythm"><div>Delayed bleeding following injury, trauma, or surgery</div></li><li class="half_rhythm"><div>In females, menorrhagia and abnormal bleeding with pregnancy</div></li></ul><p>Absence of other known bleeding disorders including:</p><ul><li class="half_rhythm"><div>von Willebrand disease</div></li><li class="half_rhythm"><div>Factor V deficiency</div></li><li class="half_rhythm"><div>Factor X deficiency</div></li><li class="half_rhythm"><div>Factor II deficiency</div></li><li class="half_rhythm"><div>Alpha 2 antiplasmin deficiency</div></li><li class="half_rhythm"><div>Factor XIII deficiency</div></li><li class="half_rhythm"><div>Platelet function disorders (including Scott syndrome and Quebec platelet disorder)</div></li></ul></div><div id="pai-1-def.Laboratory_Findings"><h4>Laboratory Findings</h4><p>Normal: common tests of coagulation including prothrombin time (PT), activated partial thromboplastin time (aPTT), and thrombin clotting time (TCT)</p><p>Abnormal tests indicative of a hyperfibrinolytic state; these may include the following:</p><ul><li class="half_rhythm"><div>Decreased plasma plasminogen</div></li><li class="half_rhythm"><div>Decreased plasma &#x003b1;-2-antiplasmin</div></li><li class="half_rhythm"><div>Decreased plasma total and free levels of tissue-type plasminogen activator antigen (t-PA)</div></li><li class="half_rhythm"><div>Shortened euglobin lysis time (ECLT) in plasma. Note: While ECLT is shortened due to excessive fibrinolysis in persons with complete PAI-1 deficiency, and ECLT and whole blood clotting assays (e.g., the thromboelastogram) can be helpful in diagnosis of hyperfibrinolytic states, these tests are insufficient to confirm or exclude the diagnosis of complete PAI-1 deficiency.</div></li></ul><p>PAI-1 specific assays:</p><ul><li class="half_rhythm"><div>PAI-1 antigen assay (to determine the level of PAI-1 antigen) can be helpful in identifying complete PAI-1 deficiency if no PAI-1 is produced, but is not helpful if dysfunctional protein is produced [<a class="bk_pop" href="#pai-1-def.REF.gupta.2014">Gupta et al 2014</a>].</div></li><li class="half_rhythm"><div>PAI-1 activity assay can be used to exclude a diagnosis of complete PAI-1 deficiency when PAI-1 activity levels are clearly within the normal range. Because the normal range of the functional PAI-1 activity assay starts at zero in most laboratories, the ability to discriminate between normal and abnormal levels of activity is limited [<a class="bk_pop" href="#pai-1-def.REF.fay.1997.204">Fay et al 1997</a>, <a class="bk_pop" href="#pai-1-def.REF.mehta.2008.1255">Mehta &#x00026; Shapiro 2008</a>].</div></li></ul><p>Note: If the PAI-1 antigen level is normal and PAI-1 activity is decreased, the <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> is referred to as "qualitative PAI-1deficiency," the clinical significance of which is unknown [<a class="bk_pop" href="#pai-1-def.REF.fay.1997.204">Fay et al 1997</a>, <a class="bk_pop" href="#pai-1-def.REF.mehta.2008.1255">Mehta &#x00026; Shapiro 2008</a>].</p></div></div><div id="pai-1-def.Establishing_the_Diagnosis"><h3>Establishing the Diagnosis</h3><p>The diagnosis of complete PAI-1 deficiency <b>is established</b> in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> when [<a class="bk_pop" href="#pai-1-def.REF.fay.1997.204">Fay et al 1997</a>, <a class="bk_pop" href="#pai-1-def.REF.iwaki.2011.1200">Iwaki et al 2011</a>]:</p><ul><li class="half_rhythm"><div class="half_rhythm">PAI-1 antigen is undetectable and PAI-1 activity is lower than 1 IU/mL</div><div class="half_rhythm">Note: (1) Because the majority of PAI-1 activity assays are used to detect increased PAI-1 activity rather than decreased PAI-1 activity, they lack the <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> to differentiate between low normal activity and complete deficiency. Thus, a PAI-1 activity level of zero is often reported to be within the normal limits. (2) PAI-1 activity also demonstrates diurnal variation: because higher levels are observed in the morning and lower levels in the afternoon, the activity should be assayed in a sample drawn in the morning.</div></li></ul><p>AND/OR</p><ul><li class="half_rhythm"><div>Biallelic <i>SERPINE1</i> pathogenic variants are identified on <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> (see <a class="figpopup" href="/books/NBK447152/table/pai-1-def.T.molecular_genetic_testing_us/?report=objectonly" target="object" rid-figpopup="figpai1defTmoleculargenetictestingus" rid-ob="figobpai1defTmoleculargenetictestingus">Table 1</a>). See also <a href="#pai-1-def.Molecular_Genetics">Molecular Genetics</a>.</div></li></ul><p>Molecular genetic testing approaches can include <b>single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing</b> and use of a <b><a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b>.</p><p><b>Single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing</b></p><ul><li class="half_rhythm"><div>Sequence analysis of <i>SERPINE1</i> is performed first. If only one or no <i>SERPINE1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is identified, <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> can be considered; however, to date no <i>SERPINE1</i> <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-gene deletions/duplications have been reported.</div></li><li class="half_rhythm"><div>Targeted analysis for the <a class="figpopup" href="/books/NBK447152/table/pai-1-def.T.serpine1_variants_discussed/?report=objectonly" target="object" rid-figpopup="figpai1defTserpine1variantsdiscussed" rid-ob="figobpai1defTserpine1variantsdiscussed">c.699_700dupTA</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> can be performed first in individuals from the Old Order Amish community of eastern and southern Indiana. Note: This variant has not been identified in other Old Order Amish populations.</div></li></ul><p><b>A <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b> that includes <i>SERPINE1</i> and other genes of interest (see <a href="#pai-1-def.Differential_Diagnosis">Differential Diagnosis</a>) may also be considered. Note: (1) The genes included in the panel and the diagnostic <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> of the testing used for each <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> vary by laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with the condition discussed in this <i>GeneReview</i>; thus, clinicians need to determine which multigene panel is most likely to identify the genetic cause of the condition at the most reasonable cost while limiting identification of variants of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a> and pathogenic variants in genes that do not explain the underlying <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>. (3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused <a class="def" href="/books/n/gene/glossary/def-item/exome/">exome</a> analysis that includes genes specified by the clinician. (4) Methods used in a panel may include <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>, <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>, and/or other non-sequencing-based tests.</p><p>For an introduction to multigene panels click <a href="/books/n/gene/app5/#app5.Multigene_Panels">here</a>. More detailed information for clinicians ordering genetic tests can be found <a href="/books/n/gene/app5/#app5.Multigene_Panels_FAQs">here</a>.</p><div id="pai-1-def.T.molecular_genetic_testing_us" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Molecular Genetic Testing Used in Plasminogen Activator Inhibitor 1 (PAI-1) Deficiency</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK447152/table/pai-1-def.T.molecular_genetic_testing_us/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__pai-1-def.T.molecular_genetic_testing_us_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_pai-1-def.T.molecular_genetic_testing_us_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene&#x000a0;<sup>1</sup></th><th id="hd_h_pai-1-def.T.molecular_genetic_testing_us_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Test Method</th><th id="hd_h_pai-1-def.T.molecular_genetic_testing_us_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Proportion of Probands with Pathogenic Variants&#x000a0;<sup>2</sup> Detectable by This Method</th></tr></thead><tbody><tr><td headers="hd_h_pai-1-def.T.molecular_genetic_testing_us_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><i>SERPINE1</i></td><td headers="hd_h_pai-1-def.T.molecular_genetic_testing_us_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis&#x000a0;<sup>3</sup></td><td headers="hd_h_pai-1-def.T.molecular_genetic_testing_us_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unknown</td></tr><tr><td headers="hd_h_pai-1-def.T.molecular_genetic_testing_us_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>&#x000a0;<sup>4</sup></td><td headers="hd_h_pai-1-def.T.molecular_genetic_testing_us_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">None reported <sup>5</sup></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="pai-1-def.TF.1.1"><p class="no_margin">See <a href="/books/n/gene/pai1-def/#pai1-def.molgen.TA">Table A. Genes and Databases</a> for <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and protein.</p></div></dd><dt>2. </dt><dd><div id="pai-1-def.TF.1.2"><p class="no_margin">See <a href="#pai-1-def.Molecular_Genetics">Molecular Genetics</a> for information on allelic variants detected in this <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>.</p></div></dd><dt>3. </dt><dd><div id="pai-1-def.TF.1.3"><p class="no_margin">Sequence analysis detects variants that are benign, likely benign, of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a>, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications are not detected. For issues to consider in interpretation of <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> results, click <a href="/books/n/gene/app2/">here</a>.</p></div></dd><dt>4. </dt><dd><div id="pai-1-def.TF.1.4"><p class="no_margin">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> detects intragenic deletions or duplications. Methods used may include: <a class="def" href="/books/n/gene/glossary/def-item/quantitative-pcr/">quantitative PCR</a>, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted microarray designed to detect single-<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> deletions or duplications.</p></div></dd><dt>5. </dt><dd><div id="pai-1-def.TF.1.5"><p class="no_margin">No data on detection rate of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> are available.</p></div></dd></dl></div></div></div></div></div><div id="pai-1-def.Clinical_Characteristics"><h2 id="_pai-1-def_Clinical_Characteristics_">Clinical Characteristics</h2><div id="pai-1-def.Clinical_Description"><h3>Clinical Description</h3><p>Untreated complete plasminogen activator inhibitor 1 (PAI-1) deficiency is characterized by mild to moderate bleeding, although in some instances bleeding can be life-threatening. Most commonly, delayed bleeding is associated with injury, trauma, or surgery; spontaneous bleeding episodes such as those observed in classic <a href="/books/n/gene/hemo-a/">hemophilia A</a> and <a href="/books/n/gene/hemo-b/">hemophilia B</a> do not occur.</p><p>While males and females with complete PAI-1 deficiency are <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> equally, females may present more frequently with clinical manifestations or earlier in life than males, due to menorrhagia and postpartum hemorrhage. In addition, females experience bleeding with pregnancy and have difficulty carrying a pregnancy to term.</p><p><b>Bleeding disorder.</b> Mucocutaneous bleeding, a hallmark of complete PAI-1 deficiency, includes oral bleeding, epistaxis and &#x02013; in females &#x02013; menorrhagia and postpartum bleeding.</p><p>Post-traumatic bleeding can include joint bleeds and hematomas [<a class="bk_pop" href="#pai-1-def.REF.schleef.1989.1747">Schleef et al 1989</a>, <a class="bk_pop" href="#pai-1-def.REF.di_val.1991.528">Di&#x000e9;val et al 1991</a>, <a class="bk_pop" href="#pai-1-def.REF.minowa.1999.286">Minowa et al 1999</a>]. Affected members of the kindred from the Old Order Amish community of eastern and southern Indiana developed knee and elbow hemarthroses after minor trauma, extensive subperiosteal bleeding after minor jaw trauma, and epidural hematoma (in an infant) after a head injury [<a class="bk_pop" href="#pai-1-def.REF.fay.1997.204">Fay et al 1997</a>].</p><p>The male reported by <a class="bk_pop" href="#pai-1-def.REF.zhang.2005.79">Zhang et al [2005]</a> experienced soft tissue hematomas of the leg and hip following minor leg trauma that required treatment; he subsequently manifested muscle atrophy.</p><p>Post-surgical bleeding has been reported in individuals with a molecularly confirmed diagnosis of complete PAI-1 deficiency:</p><ul><li class="half_rhythm"><div>A child age five years experienced postoperative bleeding following surgical repair of a ventricular septal defect [<a class="bk_pop" href="#pai-1-def.REF.iwaki.2011.1200">Iwaki et al 2011</a>].</div></li><li class="half_rhythm"><div>A member of the Old Order Amish community had delayed bleeding after surgical repair of an inguinal hernia [<a class="bk_pop" href="#pai-1-def.REF.fay.1997.204">Fay et al 1997</a>].</div></li><li class="half_rhythm"><div>Delayed bleeding was reported after total hip arthroplasty [<a class="bk_pop" href="#pai-1-def.REF.hirose.2016.e237">Hirose et al 2016</a>].</div></li></ul><p>Prolonged bleeding after dental extraction has been reported in individuals with a molecularly confirmed diagnosis of complete PAI-1 deficiency [<a class="bk_pop" href="#pai-1-def.REF.fay.1997.204">Fay et al 1997</a>, <a class="bk_pop" href="#pai-1-def.REF.iwaki.2011.1200">Iwaki et al 2011</a>].</p><p>A palatal hemorrhage complicated a dental abscess, requiring hospitalization and transfusion [<a class="bk_pop" href="#pai-1-def.REF.fay.1992.1729">Fay et al 1992</a>].</p><p>Prolonged wound healing occurred in one individual [<a class="bk_pop" href="#pai-1-def.REF.iwaki.2011.1200">Iwaki et al 2011</a>].</p><p>Menorrhagia is a consistent characteristic of complete PAI-1 deficiency [<a class="bk_pop" href="#pai-1-def.REF.minowa.1999.286">Minowa et al 1999</a>, <a class="bk_pop" href="#pai-1-def.REF.mehta.2008.1255">Mehta &#x00026; Shapiro 2008</a>, <a class="bk_pop" href="#pai-1-def.REF.iwaki.2011.1200">Iwaki et al 2011</a>]. In some instances treatment with transfusion of packed red blood cells [<a class="bk_pop" href="#pai-1-def.REF.mehta.2008.1255">Mehta &#x00026; Shapiro 2008</a>] or whole blood is required [<a class="bk_pop" href="#pai-1-def.REF.iwaki.2011.1200">Iwaki et al 2011</a>].</p><p>In one woman rupture of an ovarian follicle resulted in hemoperitoneum requiring hospitalization, treatment with antifibrinolytics, and red cell transfusion.</p><p>Pregnancy can be complicated by <a class="def" href="/books/n/gene/glossary/def-item/sporadic/">sporadic</a> antenatal bleeding, preterm labor, postpartum bleeding, and miscarriage. <a class="bk_pop" href="#pai-1-def.REF.gupta.2014">Gupta et al [2014]</a> (<a href="http://www.rarecoagulationdisorders.org/diseases/plasminogen-activator-inhibitor-type-1-deficiency/disease-overview-2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">full text</a>) followed two women with PAI-1 deficiency through a total of seven pregnancies: six live born premature infants and one miscarriage. Bleeding, which began between eight and 19 weeks&#x02019; gestation and recurred prior to delivery, was treated with epsilon-aminocaproic acid (EACA). Postpartum bleeding was treated with EACA for up to six weeks (see <a href="#pai-1-def.Pregnancy_Management">Pregnancy Management</a>).</p><p><a class="bk_pop" href="#pai-1-def.REF.iwaki.2012.e161">Iwaki et al [2012]</a> also reported on three pregnancies in a woman with complete PAI-1 deficiency in which antenatal bleeding, preterm labor, and miscarriage were complications.</p><p><b>Cardiac fibrosis.</b> Cardiac fibrosis has only been reported in an Old Order Amish kindred with complete PAI-1 deficiency, which is &#x02013; to the authors' knowledge &#x02013; the largest number of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals with this finding reported to date [<a class="bk_pop" href="#pai-1-def.REF.flevaris.2017.664">Flevaris et al 2017</a>; Author, personal observation]. Of the seven individuals with cardiac fibrosis, one had severe involvement and six had minimal to moderate cardiac fibrosis between ages 15 and 35 years. Thus, to date, information about cardiac fibrosis in complete PAI-1 deficiency is limited.</p></div><div id="pai-1-def.GenotypePhenotype_Correlations"><h3>Genotype-Phenotype Correlations</h3><p>Because data on the <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> associated with <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> <i>SERPINE1</i> pathogenic variants are limited, no <a class="def" href="/books/n/gene/glossary/def-item/genotype-phenotype-correlations/">genotype-phenotype correlations</a> can be made at this time.</p></div><div id="pai-1-def.Nomenclature"><h3>Nomenclature</h3><p>Complete plasminogen activator inhibitor 1 (PAI-1) deficiency, the topic of this <i>GeneReview</i>, is defined as undetectable PAI-1 antigen levels and undetectable PAI-1 activity. Complete PAI-1 deficiency may also be referred to as "quantitative PAI-1 deficiency" or "<a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> PAI-1 deficiency."</p><p>Qualitative PAI-1 deficiency, not addressed in this <i>GeneReview</i>, refers to normal PAI-1 antigen levels and decreased PAI-1 activity and is thought to be associated with either a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <i>SERPINE1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> (i.e., the <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> state for an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> disorder) or compound heterozygosity for variants that produce a reduced amount of protein that is nonetheless sufficient to avoid complete deficiency. The clinical significance of qualitative PAI-1 deficiency is unknown. See also <a href="#pai-1-def.Molecular_Genetics">Molecular Genetics</a>.</p></div><div id="pai-1-def.Prevalence"><h3>Prevalence</h3><p>The prevalence of complete PAI-1 deficiency is unknown, in large part because of the inability of the majority of tests of PAI-1 activity to differentiate between low normal activity and complete deficiency (see <a href="#pai-1-def.Establishing_the_Diagnosis">Establishing the Diagnosis</a>).</p><p>Fewer than ten families with complete PAI-1 deficiency have been reported to date.</p><p>Complete PAI-1 deficiency has no known racial or ethnic predominance. It has been reported in North America, Europe, and Asia.</p><p>Of note, the incidence of complete PAI-1 deficiency is higher than expected in the genetic isolate of the Old Order Amish population of eastern and southern Indiana due to a pathogenic <a class="def" href="/books/n/gene/glossary/def-item/founder-variant/">founder variant</a> (see <a href="#pai-1-def.Molecular_Genetics">Molecular Genetics</a>). To date, this <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> has not been found in other Old Order Amish communities.</p></div></div><div id="pai-1-def.Genetically_Related_Allelic_Di"><h2 id="_pai-1-def_Genetically_Related_Allelic_Di_">Genetically Related (Allelic) Disorders</h2><p>No other phenotypes are known to be associated with <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> <i>SERPINE1</i> pathogenic variants.</p></div><div id="pai-1-def.Differential_Diagnosis"><h2 id="_pai-1-def_Differential_Diagnosis_">Differential Diagnosis</h2><div id="pai-1-def.T.disorders_associated_with_mi" class="table"><h3><span class="label">Table 2. </span></h3><div class="caption"><p>Disorders Associated with Mild to Moderate Bleeding (often Associated with Injury, Surgery, or Dental Procedures) to Consider in the Differential Diagnosis of Complete PAI-1 Deficiency</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK447152/table/pai-1-def.T.disorders_associated_with_mi/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__pai-1-def.T.disorders_associated_with_mi_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_pai-1-def.T.disorders_associated_with_mi_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Disorder&#x000a0;<sup>1</sup></th><th id="hd_h_pai-1-def.T.disorders_associated_with_mi_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene(s)</th><th id="hd_h_pai-1-def.T.disorders_associated_with_mi_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">MOI</th><th id="hd_h_pai-1-def.T.disorders_associated_with_mi_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Clinical Feature Unique to Differential Diagnosis Disorder</th><th id="hd_h_pai-1-def.T.disorders_associated_with_mi_1_1_1_5" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Related <i>GeneReview</i> / OMIM Entry</th></tr></thead><tbody><tr><td headers="hd_h_pai-1-def.T.disorders_associated_with_mi_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Alpha-2 antiplasmin deficiency</td><td headers="hd_h_pai-1-def.T.disorders_associated_with_mi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>SERPINF2</i></td><td headers="hd_h_pai-1-def.T.disorders_associated_with_mi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_pai-1-def.T.disorders_associated_with_mi_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Abnormal PLI assay&#x000a0;<sup>2</sup></td><td headers="hd_h_pai-1-def.T.disorders_associated_with_mi_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="https://omim.org/entry/262850" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">262850</a></td></tr><tr><td headers="hd_h_pai-1-def.T.disorders_associated_with_mi_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Factor XIII deficiency</td><td headers="hd_h_pai-1-def.T.disorders_associated_with_mi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>F13A1, F13B</i></td><td headers="hd_h_pai-1-def.T.disorders_associated_with_mi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_pai-1-def.T.disorders_associated_with_mi_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Low factor XIII level</td><td headers="hd_h_pai-1-def.T.disorders_associated_with_mi_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="https://omim.org/entry/613225" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">613225</a></td></tr><tr><td headers="hd_h_pai-1-def.T.disorders_associated_with_mi_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Factor II deficiency</td><td headers="hd_h_pai-1-def.T.disorders_associated_with_mi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>F2</i></td><td headers="hd_h_pai-1-def.T.disorders_associated_with_mi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_pai-1-def.T.disorders_associated_with_mi_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Low factor II level</td><td headers="hd_h_pai-1-def.T.disorders_associated_with_mi_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="https://omim.org/entry/613679" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">613679</a></td></tr><tr><td headers="hd_h_pai-1-def.T.disorders_associated_with_mi_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Factor V deficiency</td><td headers="hd_h_pai-1-def.T.disorders_associated_with_mi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>F5</i></td><td headers="hd_h_pai-1-def.T.disorders_associated_with_mi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_pai-1-def.T.disorders_associated_with_mi_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Low factor V level</td><td headers="hd_h_pai-1-def.T.disorders_associated_with_mi_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="https://omim.org/entry/227400" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">227400</a></td></tr><tr><td headers="hd_h_pai-1-def.T.disorders_associated_with_mi_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Factor X deficiency</td><td headers="hd_h_pai-1-def.T.disorders_associated_with_mi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>F10</i></td><td headers="hd_h_pai-1-def.T.disorders_associated_with_mi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_pai-1-def.T.disorders_associated_with_mi_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Low factor X level</td><td headers="hd_h_pai-1-def.T.disorders_associated_with_mi_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="https://omim.org/entry/227600" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">227600</a></td></tr><tr><td headers="hd_h_pai-1-def.T.disorders_associated_with_mi_1_1_1_1" rowspan="6" scope="row" colspan="1" style="text-align:left;vertical-align:middle;">Platelet function defects</td><td headers="hd_h_pai-1-def.T.disorders_associated_with_mi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>GP1BA</i></td><td headers="hd_h_pai-1-def.T.disorders_associated_with_mi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_pai-1-def.T.disorders_associated_with_mi_1_1_1_4" rowspan="6" colspan="1" style="text-align:left;vertical-align:middle;">Abnormal platelet studies</td><td headers="hd_h_pai-1-def.T.disorders_associated_with_mi_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="https://omim.org/entry/177820" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">177820</a></td></tr><tr><td headers="hd_h_pai-1-def.T.disorders_associated_with_mi_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;"><i>GP1BB</i></td><td headers="hd_h_pai-1-def.T.disorders_associated_with_mi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_pai-1-def.T.disorders_associated_with_mi_1_1_1_5" rowspan="2" colspan="1" style="text-align:left;vertical-align:middle;"><a href="https://omim.org/entry/231200" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">231200</a></td></tr><tr><td headers="hd_h_pai-1-def.T.disorders_associated_with_mi_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;"><i>GP9</i></td><td headers="hd_h_pai-1-def.T.disorders_associated_with_mi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td></tr><tr><td headers="hd_h_pai-1-def.T.disorders_associated_with_mi_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;"><i>ANO6</i></td><td headers="hd_h_pai-1-def.T.disorders_associated_with_mi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AR</td><td headers="hd_h_pai-1-def.T.disorders_associated_with_mi_1_1_1_5" colspan="1" rowspan="1" style="text-align:left;vertical-align:middle;"><a href="https://omim.org/entry/262890" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">262890</a></td></tr><tr><td headers="hd_h_pai-1-def.T.disorders_associated_with_mi_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;"><i>ITGA2B</i></td><td headers="hd_h_pai-1-def.T.disorders_associated_with_mi_1_1_1_3" rowspan="2" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_pai-1-def.T.disorders_associated_with_mi_1_1_1_5" rowspan="2" colspan="1" style="text-align:left;vertical-align:middle;"><a href="https://omim.org/entry/187800" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">187800</a></td></tr><tr><td headers="hd_h_pai-1-def.T.disorders_associated_with_mi_1_1_1_2" colspan="1" scope="col" rowspan="1" style="text-align:left;vertical-align:middle;"><i>ITGB3</i></td></tr><tr><td headers="hd_h_pai-1-def.T.disorders_associated_with_mi_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">von Willebrand disease (VWD)</td><td headers="hd_h_pai-1-def.T.disorders_associated_with_mi_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>VWF</i></td><td headers="hd_h_pai-1-def.T.disorders_associated_with_mi_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD, AR</td><td headers="hd_h_pai-1-def.T.disorders_associated_with_mi_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Abnormal VWD lab evaluation</td><td headers="hd_h_pai-1-def.T.disorders_associated_with_mi_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/von-willebrand/">von Willebrand Disease</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">AD = <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a>; AR = <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a>; MOI = <a class="def" href="/books/n/gene/glossary/def-item/mode-of-inheritance/">mode of inheritance</a></p></div></dd><dt>1. </dt><dd><div id="pai-1-def.TF.2.1"><p class="no_margin">Disorders are listed alphabetically.</p></div></dd><dt>2. </dt><dd><div id="pai-1-def.TF.2.2"><p class="no_margin">Alpha-2 antiplasmin deficiency. Moderate bleeding seen in alpha-2 antiplasmin deficiency is not characteristically associated with injury, surgery, or dental procedures.</p></div></dd></dl></div></div></div></div><div id="pai-1-def.Management"><h2 id="_pai-1-def_Management_">Management</h2><div id="pai-1-def.Evaluations_Following_Initial"><h3>Evaluations Following Initial Diagnosis</h3><p>To establish the extent of disease and needs in an individual diagnosed with complete plasminogen activator inhibitor 1 (PAI-1) deficiency, the following evaluations are recommended:</p><ul><li class="half_rhythm"><div class="half_rhythm">Questions to elicit a patient's history of:</div><ul><li class="half_rhythm"><div>Epistaxis</div></li><li class="half_rhythm"><div>Poor wound healing</div></li><li class="half_rhythm"><div>Bleeding in association with injury or trauma</div></li><li class="half_rhythm"><div>Bleeding with dental extractions</div></li><li class="half_rhythm"><div>Additional oral bleeding</div></li><li class="half_rhythm"><div>Post-surgical bleeding</div></li><li class="half_rhythm"><div>In females:</div><ul><li class="half_rhythm"><div>Heavy menstrual bleeding</div></li><li class="half_rhythm"><div>Postpartum bleeding</div></li><li class="half_rhythm"><div>Bleeding during pregnancy</div></li><li class="half_rhythm"><div>Preterm delivery</div></li><li class="half_rhythm"><div>Bleeding in association with ovulation</div></li></ul></li></ul></li><li class="half_rhythm"><div class="half_rhythm">History of therapies tried in the past and the response to each specific therapy</div><div class="half_rhythm">Note that response to antifibrinolytic therapy supports the diagnosis of complete PAI-1 deficiency (see <a href="#pai-1-def.Treatment_of_Manifestations">Treatment of Manifestations</a>).</div></li><li class="half_rhythm"><div class="half_rhythm">Evaluation by a hematologist with training in hemostasis</div></li><li class="half_rhythm"><div class="half_rhythm">Consultation with a clinical geneticist and/or genetic counselor</div></li></ul></div><div id="pai-1-def.Treatment_of_Manifestations"><h3>Treatment of Manifestations</h3><p><b>Bleeding disorder.</b> Management by a team of experts in the treatment of individuals with bleeding disorders is highly recommended. In the US, such teams are often identified through the <a href="http://www.cdc.gov/ncbddd/hemophilia/HTC.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">federally funded hemophilia treatment center network</a>.</p><p>Severe bleeding manifestations, including intracranial hemorrhage (with or without hematoma evacuation) have been successfully managed with intravenous antifibrinolytics. Response to both epsilon-aminocaproic acid and tranexamic acid have been documented.</p><p>If PAI-1 activity needs to be increased prior to achieving the therapeutic steady state level of antifibrinolytics, infusion of fresh-frozen plasma (FFP) (10-15 mL/kg) can be used. Duration of use of FFP is individualized based on clinical course and response to therapy. Note: The use of FFP does not appear to be effective in pregnancy for the prevention of bleeding in women with complete PAI-1 deficiency [<a class="bk_pop" href="#pai-1-def.REF.iwaki.2012.e161">Iwaki et al 2012</a>]. Fresh-frozen plasma to replace PAI-1 during pregnancy may be difficult due to the PAI-1 level achieved with plasma, the volume required, and the need for repeated infusion, all of which may be associated with risk of volume overload and/or infusion reactions [<a class="bk_pop" href="#pai-1-def.REF.gupta.2014">Gupta et al 2014</a>].</p><p>Heavy menstrual bleeding can often be effectively managed with antifibrinolytics or hormonal suppression therapy (oral contraceptives).</p><p>Occasionally, patients with complete PAI-1 deficiency experience excessive menstrual bleeding or bleeding following a procedure or trauma that requires infusion of packed red blood cells to manage the acute blood loss.</p><p>Education regarding bleeding manifestations and when to seek treatment includes the following:</p><ul><li class="half_rhythm"><div>For females, anticipatory counseling regarding onset of menses and potential complications</div></li><li class="half_rhythm"><div>Prompt reporting of injuries and planned procedures to allow early initiation of treatment to prevent significant bleeding</div></li></ul><p><b>Cardiac fibrosis</b>. There is currently no specific treatment for cardiac fibrosis associated with complete PAI-1 deficiency; treatment is symptomatic.</p></div><div id="pai-1-def.Prevention_of_Primary_Manifest"><h3>Prevention of Primary Manifestations</h3><p>Antifibrinolytics should be used to prevent bleeding for surgical and dental procedures, childbirth, and other invasive procedures. Antifibrinolytics can be administered IV, PO, or topically, the latter especially during dental procedures.</p><p>Women who have heavy menstrual bleeding often benefit from continuous or intermittent prophylactic use of the antifibrinolytics tranexamic acid and epsilon-aminocaproic acid.</p></div><div id="pai-1-def.Surveillance"><h3>Surveillance</h3><p><b>Bleeding disorder.</b> Regular follow up with a team of experts in the treatment of individuals with bleeding disorders is recommended. Such teams are often identified through the <a href="http://www.cdc.gov/ncbddd/hemophilia/HTC.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">federal hemophilia treatment center network</a> in the US.</p><p>For menstruating females:</p><ul><li class="half_rhythm"><div>Regular monitoring: hemoglobin and/or hematocrit and iron studies including ferritin for possible iron deficiency and/or anemia</div></li><li class="half_rhythm"><div>Assessment of the effectiveness of therapeutic interventions such as antifibrinolytics or hormonal suppressive agents (oral contraceptives)</div></li></ul><p><b>Cardiac fibrosis.</b> Because of clinical experience (albeit limited to date) with cardiac fibrosis in persons with complete PAI-1 deficiency [<a class="bk_pop" href="#pai-1-def.REF.flevaris.2017.664">Flevaris et al 2017</a>; Author, personal observation], screening echocardiogram can be considered beginning at age 15 years. In those with no cardiac findings, follow-up screening in two years is indicated; and in those with cardiac findings, follow up yearly or more frequently if indicated by a cardiologist [<a class="bk_pop" href="#pai-1-def.REF.ghosh.2010.1200">Ghosh et al 2010</a>; <a class="bk_pop" href="#pai-1-def.REF.ghosh.2013.e63825">Ghosh et al 2013</a>; Author, personal observation].</p></div><div id="pai-1-def.AgentsCircumstances_to_Avoid"><h3>Agents/Circumstances to Avoid</h3><p>The following should be avoided:</p><ul><li class="half_rhythm"><div>Medications that affect coagulation including aspirin, ibuprofen, and some herbal remedies</div></li><li class="half_rhythm"><div>High-risk activities such as contact sports</div></li></ul></div><div id="pai-1-def.Evaluation_of_Relatives_at_Ris"><h3>Evaluation of Relatives at Risk</h3><p>It is appropriate to clarify the genetic status of apparently asymptomatic older and younger sibs of an individual with complete PAI-1 deficiency in order to identify as early as possible those who would benefit from prompt initiation of treatment and preventive measures.</p><p>Evaluations can include:</p><ul><li class="half_rhythm"><div>Molecular genetic testing if the <i>SERPINE1</i> pathogenic variants in the family are known;</div></li><li class="half_rhythm"><div>Measurement of PAI-1 antigen levels and PAI-1 activity if the <i>SERPINE1</i> pathogenic variants in the family are not known.</div></li></ul><p>See <a href="#pai-1-def.Related_Genetic_Counseling_Iss">Genetic Counseling</a> for issues related to testing of at-risk relatives for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> purposes.</p></div><div id="pai-1-def.Pregnancy_Management"><h3>Pregnancy Management</h3><p>Recommendations based on published findings during pregnancies in two women with complete PAI-1 deficiency are administration of either tranexamic acid (25 mg kg-1 per dose, maximum 1300 milligrams, orally 3-4x/day) or epsilon-aminocaproic acid (EACA) (100 mg kg-1 per dose, maximum 3 g, orally 4x/day) for intermittent bleeding in the first and second trimester, from 26 weeks&#x02019; gestation through delivery, and for at least two weeks post partum [<a class="bk_pop" href="#pai-1-def.REF.heiman.2014.407">Heiman et al 2014</a>]. Note that evidence that these recommendations would be effective in all pregnancies of women with complete PAI-1 deficiency is lacking.</p><p>A woman with complete PAI-1 deficiency was treated with FFP during three pregnancies at eight to 11 weeks' gestation two to three times per week; treatment was increased to daily at 20-28 weeks' gestation. The first pregnancy ended in miscarriage at 19 weeks. The second and third pregnancies were delivered at 32 and 27 weeks&#x02019; gestation, respectively, as a result of uncontrollable contractions and placental abruption [<a class="bk_pop" href="#pai-1-def.REF.iwaki.2012.e161">Iwaki et al 2012</a>].</p><p>Of note, the teratogenicity of EACA and tranexamic acid is unknown and information regarding their safety during pregnancy and lactation is limited. There is a need to establish dosing guidelines for the use of antifibrinolytics during pregnancy and the postpartum period.</p><p>See <a href="http://www.mothertobaby.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.mothertobaby.org</a> for further information on medication use during pregnancy.</p></div><div id="pai-1-def.Therapies_Under_Investigation"><h3>Therapies Under Investigation</h3><p>Search <a href="https://clinicaltrials.gov/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a> in the US and <a href="http://www.ClinicalTrialsRegister.eu" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.ClinicalTrialsRegister.eu</a> in Europe for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.</p></div></div><div id="pai-1-def.Genetic_Counseling"><h2 id="_pai-1-def_Genetic_Counseling_">Genetic Counseling</h2><p>
<i>Genetic counseling is the process of providing individuals and families with
information on the nature, inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with a genetics
professional</i>. &#x02014;ED.</p><div id="pai-1-def.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p>Complete plasminogen activator inhibitor 1 (PAI-1) deficiency is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-recessive/">autosomal recessive</a> manner.</p></div><div id="pai-1-def.Risk_to_Family_Members"><h3>Risk to Family Members</h3><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>The parents of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual are obligate heterozygotes (i.e., carriers of one <i>SERPINE1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>).</div></li><li class="half_rhythm"><div>Heterozygotes (carriers) are asymptomatic and are not at risk of developing complete PAI-1 deficiency.</div></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>At conception, each sib of an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual has a 25% chance of being affected, a 50% chance of being an asymptomatic <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a>, and a 25% chance of being unaffected and not a carrier.</div></li><li class="half_rhythm"><div>Heterozygotes (carriers) are asymptomatic and are not at risk of developing complete PAI-1 deficiency.</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>The offspring of an individual with complete PAI-1 deficiency are obligate heterozygotes (carriers) for a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>SERPINE1.</i></div></li><li class="half_rhythm"><div>The incidence of PAI-1 deficiency is higher than expected in the genetic isolate of the Old Order Amish population of eastern and southern Indiana, increasing the risk that an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual may have a reproductive partner who is <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for a <i>SERPINE1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> (see <a href="#pai-1-def.Prevalence">Prevalence</a>). The offspring of an affected individual and a heterozygous reproductive partner are at 50% risk of being affected and 50% risk of being heterozygous.</div></li></ul><p><b>Other family members.</b> Each sib of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>&#x02019;s parents is at a 50% risk of being a <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> of a <i>SERPINE1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</p></div><div id="pai-1-def.Carrier_Heterozygote_Detection"><h3>Carrier (Heterozygote) Detection</h3><p>Carrier testing for at-risk relatives requires prior identification of the <i>SERPINE1</i> pathogenic variants in the family.</p></div><div id="pai-1-def.Related_Genetic_Counseling_Iss"><h3>Related Genetic Counseling Issues</h3><p>See Management, <a href="#pai-1-def.Evaluation_of_Relatives_at_Ris">Evaluation of Relatives at Risk</a> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p><p><b>Family planning</b></p><ul><li class="half_rhythm"><div>The optimal time for determination of genetic risk, clarification of <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> status, and discussion of the availability of prenatal testing is before pregnancy.</div></li><li class="half_rhythm"><div>It is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> (including discussion of potential risks to offspring and reproductive options) to young adults who are <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>, are carriers, or are at risk of being carriers. This includes issues related to pregnancy in affected women and the risk to the fetus due to risk for prematurity.</div></li></ul><p><b>DNA banking</b> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div><div id="pai-1-def.Prenatal_Testing_and_Preimplan"><h3>Prenatal Testing and Preimplantation Genetic Diagnosis</h3><p>Once the <i>SERPINE1</i> pathogenic variants have been identified in an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family member, prenatal testing for a pregnancy at increased risk and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> for complete PAI-1 deficiency are possible.</p><p>Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather than early diagnosis. While most centers would consider decisions regarding prenatal testing to be the choice of the parents, discussion of these issues is appropriate.</p></div></div><div id="pai-1-def.Resources"><h2 id="_pai-1-def_Resources_">Resources</h2><p>
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/">here</a>.</i></p><ul><li class="half_rhythm"><div><b>Rare Coagulation Disorders Resource Room</b></div><div><a href="http://www.rarecoagulationdisorders.org/diseases/plasminogen-activator-inhibitor-type-1-deficiency/disease-overview-2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Plasminogen Activator Inhibitor Type 1 Deficiency</a></div></li><li class="half_rhythm"><div><b>Rare Coagulation Disorders Resource Room </b></div><div><a href="http://www.rarecoagulationdisorders.org/diseases/plasminogen-activator-inhibitor-type-1-deficiency/resources" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Patient Advocacy and Support Groups</a></div></li><li class="half_rhythm"><div><b>National Hemophilia Foundation (NHF)</b></div><div>116 West 32nd Street</div><div>11th Floor</div><div>New York NY 10001</div><div><b>Phone:</b> 212-328-3700</div><div><b>Fax:</b> 212-328-3777</div><div><b>Email:</b> handi@hemophilia.org</div><div><a href="http://www.hemophilia.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.hemophilia.org</a></div></li></ul></div><div id="pai-1-def.Molecular_Genetics"><h2 id="_pai-1-def_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. &#x02014;</i>ED.</p><div id="pai-1-def.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>Complete Plasminogen Activator Inhibitor 1 Deficiency: Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK447152/table/pai-1-def.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__pai-1-def.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_pai-1-def.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_pai-1-def.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_pai-1-def.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_pai-1-def.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Locus-Specific Databases</th><th id="hd_b_pai-1-def.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_pai-1-def.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_pai-1-def.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/5054" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>SERPINE1</i></a></td><td headers="hd_b_pai-1-def.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=5054" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">7q22<wbr style="display:inline-block"></wbr>​.1</a></td><td headers="hd_b_pai-1-def.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/P05121" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Plasminogen activator inhibitor 1</a></td><td headers="hd_b_pai-1-def.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://databases.lovd.nl/shared/genes/SERPINE1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">SERPINE1 database</a></td><td headers="hd_b_pai-1-def.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=SERPINE1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">SERPINE1</a></td><td headers="hd_b_pai-1-def.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=SERPINE1[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">SERPINE1</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div id="pai-1-def.TFA.1"><p class="no_margin">Data are compiled from the following standard references: <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> from
<a href="http://www.genenames.org/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HGNC</a>;
<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> from
<a href="http://www.omim.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM</a>;
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UniProt</a>.
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
<a href="/books/n/gene/app1/">here</a>.</p></div></dd></dl></div></div></div><div id="pai-1-def.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for Complete Plasminogen Activator Inhibitor 1 Deficiency (<a href="/omim/173360,613329" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK447152/table/pai-1-def.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__pai-1-def.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/173360" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">173360</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">SERPIN PEPTIDASE INHIBITOR, CLADE E (NEXIN, PLASMINOGEN ACTIVATOR INHIBITOR TYPE 1), MEMBER 1; SERPINE1</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/613329" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">613329</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">PLASMINOGEN ACTIVATOR INHIBITOR-1 DEFICIENCY</td></tr></tbody></table></div></div><p><b>Molecular Genetic Pathogenesis</b></p><p>PAI-1, a protein that is a member of the serine protease inhibitor (SERPIN) superfamily, is involved in a variety of pathophysiologic systems including embryogenesis, angiogenesis, ovulation, inflammation, and tumor metastasis. These observations suggest that the plasminogen activation system is an important mediator of tissue remodeling and cell migration [<a class="bk_pop" href="#pai-1-def.REF.gupta.2014">Gupta et al 2014</a>] (<a href="http://www.rarecoagulationdisorders.org/diseases/plasminogen-activator-inhibitor-type-1-deficiency/disease-overview-2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">full text</a>).</p><p>In hemostasis, PAI regulates fibrinolysis (i.e., the degradation of thrombi) [<a class="bk_pop" href="#pai-1-def.REF.gupta.2014">Gupta et al 2014</a>]. PAI-1 is an inhibitor of tissue type plasminogen activators (t-PA) and urokinase type plasminogen activators (u-PA), which convert plasminogen to plasmin, the primary protease responsible for fibrinolysis. Thus, complete PAI-1 deficiency results in excessive fibrinolysis manifesting as mild to moderate bleeding [<a class="bk_pop" href="#pai-1-def.REF.heiman.2014.407">Heiman et al 2014</a>]. Physiologic fibrinolysis occurs exclusively on the clot surface within a blood vessel and not in the circulation [<a class="bk_pop" href="#pai-1-def.REF.gupta.2014">Gupta et al 2014</a>] (see <a class="figpopup" href="/books/NBK447152/figure/pai-1-def.F1/?report=objectonly" target="object" rid-figpopup="figpai1defF1" rid-ob="figobpai1defF1">Figure 1</a>).</p><div class="iconblock whole_rhythm clearfix ten_col fig" id="figpai1defF1" co-legend-rid="figlgndpai1defF1"><a href="/books/NBK447152/figure/pai-1-def.F1/?report=objectonly" target="object" title="Figure1. " class="img_link icnblk_img figpopup" rid-figpopup="figpai1defF1" rid-ob="figobpai1defF1"><img class="small-thumb" src="/books/NBK447152/bin/pai-1-def-Image001.gif" src-large="/books/NBK447152/bin/pai-1-def-Image001.jpg" alt="Figure1. . Plasminogen activators &#x02013; urokinase plasminogen activator (u-PA) and tissue plasminogen activator (t-PA) &#x02013; circulate in plasma as a reversible complex with PAI-1." /></a><div class="icnblk_cntnt" id="figlgndpai1defF1"><h4 id="pai-1-def.F1"><a href="/books/NBK447152/figure/pai-1-def.F1/?report=objectonly" target="object" rid-ob="figobpai1defF1">Figure1. </a></h4><p class="float-caption no_bottom_margin">Plasminogen activators &#x02013; urokinase plasminogen activator (u-PA) and tissue plasminogen activator (t-PA) &#x02013; circulate in plasma as a reversible complex with PAI-1. When the fibrin clot is formed, plasminogen and t-PA or u-PA bind to the <a href="/books/NBK447152/figure/pai-1-def.F1/?report=objectonly" target="object" rid-ob="figobpai1defF1">(more...)</a></p></div></div><p>Heterozygous pathogenic variants in <i>SERPINE1</i> may be associated with qualitative PAI-1 deficiency (i.e., normal PAI-1 antigen levels and decreased PAI-1 activity), the clinical significance of which is unknown. Thus, the significance of reports of families with qualitative PAI-1 deficiency and a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <i>SERPINE1</i> variant should be interpreted with caution because (1) the PAI-1 activity assays used in these families lack the <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> to differentiate between low normal activity and complete deficiency, and (2) the <i>SERPINE1</i> variants identified are of uncertain clinical significance (i.e., some variants reported as pathogenic may actually be benign).</p><p>Although beyond the scope of diagnostic laboratories, studies to determine the functional consequences of a <i>SERPINE1</i> variant may be of value in these circumstances. Of note, in vitro expression analyses demonstrated that the c.699_700dupTA variant of the Old Order Amish community resulted in the synthesis of an insoluble, unstable protein [<a class="bk_pop" href="#pai-1-def.REF.fay.1992.1729">Fay et al 1992</a>]. However, currently there are no clinically useful functional PAI-1 assays. Note: A fibrinolysis assay with a euglobulin clot lysis time is not sensitive or specific to PAI-1.</p><p><b>Gene structure.</b>
<i>SERPINE1</i> spans approximately 12 kb and comprises nine exons. A variety of regulatory elements have been identified in <i>SERPINE1</i>, including AP-1 sites, a glucocorticoid response element, a VLDL response site, and two Sp1 sites that appear to mediate glucose responsiveness. See <a href="/books/NBK447152/#pai-1-def.molgen.TA">Table A</a>, <b>Gene</b> for a detailed summary of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> and protein information.</p><p><b>Modulator.</b> The <i>SERPINE1</i> c.-820_-817G(4_5) (commonly known as 4G/5G) <a class="def" href="/books/n/gene/glossary/def-item/benign-variant/">benign variant</a> is a common <a class="def" href="/books/n/gene/glossary/def-item/insertion/">insertion</a>/<a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a> of four or five G-nucleotide residues in the <i>SERPINE1</i> <a class="def" href="/books/n/gene/glossary/def-item/promoter-region/">promoter region</a>; the 4G <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> is associated with higher plasma PAI-1 activity. An elevation in plasma PAI-1 activity leads to depressed fibrinolytic activity and a theoretically increased risk for arterial and venous thrombosis, a significant risk factor for coronary artery disease, myocardial infarction, and recurrent miscarriage [<a class="bk_pop" href="#pai-1-def.REF.huang.2017.1551">Huang et al 2017</a>]. This benign variant is mentioned only to point out that testing for the 4G/5G variant will <i>not</i> aid in diagnosing an individual with complete PAI-1 deficiency.</p><p><b>Pathogenic variants.</b> The first individual reported to have a bleeding disorder resulting from <a class="def" href="/books/n/gene/glossary/def-item/biallelic/">biallelic</a> <i>SERPINE1</i> pathogenic variants was a child from the Old Order Amish community of eastern and southern Indiana who was <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> for a dinucleotide <a class="def" href="/books/n/gene/glossary/def-item/insertion/">insertion</a> in <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 4 (c.699_700dupTA), resulting in a frameshift leading to a premature stop codon [<a class="bk_pop" href="#pai-1-def.REF.fay.1992.1729">Fay et al 1992</a>]. Subsequently in this Old Order Amish community: (1) eleven additional individuals with a bleeding disorder have been determined to be homozygous for this <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, and (2) 96 individuals <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> for this pathogenic variant &#x02013; none of whom experienced bleeding &#x02013; have been identified [Indiana Hemophilia and Thrombosis Center, unpublished data].</p><p>Since 1992 two additional <i>SERPINE1</i> pathogenic variants associated with a bleeding disorder have been reported:</p><ul><li class="half_rhythm"><div><b>c.43G&#x0003e;A.</b> A Chinese man age 34 years with a lifelong history of bleeding associated with surgery and trauma had a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> <i>SERPINE1</i> variant; the authors ultimately concluded that a second <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> was present but undetectable [<a class="bk_pop" href="#pai-1-def.REF.zhang.2005.79">Zhang et al 2005</a>].</div></li><li class="half_rhythm"><div><b>c.356dupC.</b> A woman age 47 years with a lifelong history of major bleeding (including extreme menorrhagia and post-surgical and postpartum bleeding) and impaired wound healing had an undetectable PAI-1 antigen level. She was <a class="def" href="/books/n/gene/glossary/def-item/homozygous/">homozygous</a> for a 1-bp <a class="def" href="/books/n/gene/glossary/def-item/duplication/">duplication</a> leading to a frameshift and a premature stop codon [<a class="bk_pop" href="#pai-1-def.REF.iwaki.2011.1200">Iwaki et al 2011</a>].</div></li></ul><div id="pai-1-def.T.serpine1_variants_discussed" class="table"><h3><span class="label">Table 3. </span></h3><div class="caption"><p><i>SERPINE1</i> Variants Discussed in This <i>GeneReview</i></p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK447152/table/pai-1-def.T.serpine1_variants_discussed/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__pai-1-def.T.serpine1_variants_discussed_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_pai-1-def.T.serpine1_variants_discussed_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Variant Classification</th><th id="hd_h_pai-1-def.T.serpine1_variants_discussed_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">DNA Nucleotide Change (Alias&#x000a0;<sup>1</sup>)</th><th id="hd_h_pai-1-def.T.serpine1_variants_discussed_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Predicted Protein Change&#x000a0;<sup>2</sup></th><th id="hd_h_pai-1-def.T.serpine1_variants_discussed_1_1_1_4" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Reference Sequences</th></tr></thead><tbody><tr><td headers="hd_h_pai-1-def.T.serpine1_variants_discussed_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><b>Modulator</b></td><td headers="hd_h_pai-1-def.T.serpine1_variants_discussed_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.-820_-817G(4_5)&#x000a0;<sup>3</sup><br />(4G/5G)</td><td headers="hd_h_pai-1-def.T.serpine1_variants_discussed_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">--</td><td headers="hd_h_pai-1-def.T.serpine1_variants_discussed_1_1_1_4" rowspan="4" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/nuccore/NM_000602.4" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_000602<wbr style="display:inline-block"></wbr>​.4</a><a href="/protein/NP_000593.1" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NP_000593<wbr style="display:inline-block"></wbr>​.1</a></td></tr><tr><td headers="hd_h_pai-1-def.T.serpine1_variants_discussed_1_1_1_1" rowspan="3" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><b>Pathogenic</b></td><td headers="hd_h_pai-1-def.T.serpine1_variants_discussed_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">c.43G&#x0003e;A</td><td headers="hd_h_pai-1-def.T.serpine1_variants_discussed_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Ala15Thr</td></tr><tr><td headers="hd_h_pai-1-def.T.serpine1_variants_discussed_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.356dupC</td><td headers="hd_h_pai-1-def.T.serpine1_variants_discussed_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Ile120AspfsTer42</td></tr><tr><td headers="hd_h_pai-1-def.T.serpine1_variants_discussed_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">c.699_700dupTA</td><td headers="hd_h_pai-1-def.T.serpine1_variants_discussed_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">p.Thr234IlefsTer45</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Note on variant classification: Variants listed in the table have been provided by the authors. <i>GeneReviews</i> staff have not independently verified the classification of variants.</p></div></dd><dt></dt><dd><div><p class="no_margin">Note on nomenclature: <i>GeneReviews</i> follows the standard naming conventions of the Human Genome Variation Society (<a href="http://varnomen.hgvs.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">varnomen<wbr style="display:inline-block"></wbr>​.hgvs.org</a>). See <a href="/books/n/gene/app3/">Quick Reference</a> for an explanation of nomenclature.</p></div></dd><dt>1. </dt><dd><div id="pai-1-def.TF.3.1"><p class="no_margin">Variant designation that does not conform to current naming conventions</p></div></dd><dt>2. </dt><dd><div id="pai-1-def.TF.3.2"><p class="no_margin">Numbering relative to full-length protein</p></div></dd><dt>3. </dt><dd><div id="pai-1-def.TF.3.3"><p class="no_margin">Not associated with the complete PAI-1 deficiency <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> but can affect measured PAI-1 activity levels. A 1-bp guanine <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a>/<a class="def" href="/books/n/gene/glossary/def-item/insertion/">insertion</a> variant in promoter (<a href="/SNP/snp_ref.cgi?rs=rs587776796" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">rs587776796</a>) associated with higher transcription and activity levels and other phenotypes, including coronary artery disease (see OMIM <a href="http://omim.org/entry/173360" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">173360</a>).</p></div></dd></dl></div></div></div><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> The full-length gene product, PAI-1, is a 47-kd protein of 402 amino acids in length including the 23-residue signal peptide. The active mature form of PAI-1 in plasma is 379 amino acids in length.</p><p>The key functional domains of the full-length protein are:</p><ul><li class="half_rhythm"><div>The Arg-Met reactive site at residues 369-370;</div></li><li class="half_rhythm"><div>A vitronectin binding site;</div></li><li class="half_rhythm"><div>Glycosylation sites at residues 232, 288, and 352.</div></li></ul><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> PAI-1 deficiency may result from either complete plasma protein deficiency (absence of PAI-1 activity and antigen) as in the kindred described above or a dysproteinemic state with presence of the antigen but absence of activity.</p><p>The <a class="def" href="/books/n/gene/glossary/def-item/loss-of-function/">loss-of-function</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> c.699-700 dup TA resides in <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> 4 of the coding sequence at amino acid 210, resulting in a frame shift and formation of a premature stop codon and the synthesis of a truncated, non-functional PAI-1 protein.</p><p>The c.43G&#x0003e;A variant in the signal peptide may partly impair secretion of PAI-1 [<a class="bk_pop" href="#pai-1-def.REF.zhang.2005.79">Zhang et al 2005</a>].</p></div><div id="pai-1-def.References"><h2 id="_pai-1-def_References_">References</h2><div id="pai-1-def.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="pai-1-def.REF.di_val.1991.528">Di&#x000e9;val J, Nguyen G, Gross S, Delobel J, Kruithof EK. A lifelong bleeding disorder associated with deficiency of plasminogen activator inhibitor type 1. <span><span class="ref-journal">Blood. </span>1991;<span class="ref-vol">77</span>:528–32.</span> [<a href="/pubmed/1899347" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1899347</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pai-1-def.REF.fay.1997.204">Fay WP, Parker AC, Condrey LR, Shapiro AD. Human plasminogen activator inhibitor -1 (PAI-1) deficiency: characterization of a large kindred with a null mutation in the PAI-1 gene. <span><span class="ref-journal">Blood. </span>1997;<span class="ref-vol">90</span>:204–8.</span> [<a href="/pubmed/9207454" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9207454</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pai-1-def.REF.fay.1992.1729">Fay WP, Shapiro AD, Shih JL, Schleef RR, Ginsburg D. Brief report: complete deficiency of plasminogen activator inhibitor type 1 due to a frameshift mutation. <span><span class="ref-journal">NEJM. </span>1992;<span class="ref-vol">327</span>:1729–33.</span> [<a href="/pubmed/1435917" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1435917</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pai-1-def.REF.flevaris.2017.664">Flevaris P, Khan SS, Eren M, Schuldt AJ, Shah SJ, Lee DC, Gupta S, Shapiro A, Burridge P, Ghosh AK, Vaughan DE. Plasminogen activator inhibitor type I controls cardiomyocyte transforming growth factor-&#x003b2; and cardiac fibrosis. <span><span class="ref-journal">Circulation. </span>2017;<span class="ref-vol">136</span>:664–79.</span> [<a href="/pmc/articles/PMC5784400/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5784400</span></a>] [<a href="/pubmed/28588076" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28588076</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pai-1-def.REF.ghosh.2010.1200">Ghosh AK, Bradham WS, Gleaves LA, De Taeye B, Murphy SB, Covington JW, Vaughan DE. Genetic deficiency of plasminogen activator inhibitor-1 promotes cardiac fibrosis in aged mice. <span><span class="ref-journal">Circulation. </span>2010;<span class="ref-vol">122</span>:1200–9.</span> [<a href="/pubmed/20823384" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20823384</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pai-1-def.REF.ghosh.2013.e63825">Ghosh AK, Murphy SB, Kishore R, Vaughan DE. Global gene expression profiling PAI-1 knockout murine heart and kidney: Molecular basis of cardiac-selective fibrosis. <span><span class="ref-journal">PLoS One. </span>2013;<span class="ref-vol">8</span>:e63825.</span> [<a href="/pmc/articles/PMC3665822/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC3665822</span></a>] [<a href="/pubmed/23724005" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 23724005</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pai-1-def.REF.gupta.2014">Gupta S, Sealls W, Shapiro AD. Plasminogen Activator Inhibitor Type 1 Deficiency &#x02013; Disease Overview. Available <a href="http://www.rarecoagulationdisorders.org/diseases/plasminogen-activator-inhibitor-type-1-deficiency/disease-overview-2" ref="pagearea=cite-ref&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">online</a>. 2014. Accessed 10-24-18.</div></li><li class="half_rhythm"><div class="bk_ref" id="pai-1-def.REF.heiman.2014.407">Heiman M, Gupta S, Shapiro AD. The obstetric, gynaecological and fertility implications of homozygous PAI-1 deficiency: single-centre experience. <span><span class="ref-journal">Haemophilia. </span>2014;<span class="ref-vol">20</span>:407–12.</span> [<a href="/pubmed/24261743" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24261743</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pai-1-def.REF.hirose.2016.e237">Hirose J, Takedani H, Kubota M, Kinkawa J, Noguchi M. Total hip arthroplasty and total knee arthroplasty in a patient with congenital deficiency of plasminogen activator inhibitor-1. <span><span class="ref-journal">Haemophilia. </span>2016;<span class="ref-vol">22</span>:e237–9.</span> [<a href="/pubmed/27030314" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27030314</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pai-1-def.REF.huang.2017.1551">Huang Z, Tang W, Chen Q, Li M, Lao S, Pan H, Huang L, Huang M, Hu X, Zhao J. Plasminogen activator inhibitor-1 polymorphism confers a genetic contribution to the risk of spontaneous abortion: an updated meta-analysis. <span><span class="ref-journal">Reprod Sci. </span>2017;<span class="ref-vol">24</span>:1551–60.</span> [<a href="/pubmed/28395596" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28395596</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pai-1-def.REF.iwaki.2012.e161">Iwaki T, Nagahashi K, Kobayashi T, Umemura K, Terao T, Kanayama N. The first report of uncontrollable subchorionic retroplacental haemorrhage inducing preterm labour in complete PAI-1 deficiency in a human. <span><span class="ref-journal">Thromb. Res. </span>2012;<span class="ref-vol">129</span>:e161–3.</span> [<a href="/pubmed/22099705" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22099705</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pai-1-def.REF.iwaki.2011.1200">Iwaki T, Tanaka A, Miyawaki Y, Suzuki A, Kobayashi T, Takamatsu J, Matsushita T, Umemura K, Urano T, Kojima T, Terao T, Kanayama N. Life-threatening hemorrhage and prolonged wound healing are remarkable phenotypes manifested by complete plasminogen activator inhibitor-1 deficiency in humans. <span><span class="ref-journal">J Thromb Haemost. </span>2011;<span class="ref-vol">9</span>:1200–6.</span> [<a href="/pubmed/21486382" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21486382</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pai-1-def.REF.kohler.2000.1792">Kohler HP, Grant PJ. Plasminogen-activator inhibitor type 1 and coronary artery disease. <span><span class="ref-journal">NEJM. </span>2000;<span class="ref-vol">342</span>:1792–801.</span> [<a href="/pubmed/10853003" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10853003</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pai-1-def.REF.mehta.2008.1255">Mehta R, Shapiro AD. Plasminogen activator inhibitor type 1 deficiency. <span><span class="ref-journal">Haemophilia. </span>2008;<span class="ref-vol">14</span>:1255–60.</span> [<a href="/pubmed/19141166" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19141166</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pai-1-def.REF.minowa.1999.286">Minowa H, Takahashi Y, Tanaka T, Naganuma K, Ida S, Maki I, Yoshioka A. Four cases of bleeding diathesis in children due to congenital plasminogen activator inhibitor-1 deficiency. <span><span class="ref-journal">Haemostasis. </span>1999;<span class="ref-vol">29</span>:286–91.</span> [<a href="/pubmed/10754381" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10754381</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pai-1-def.REF.schleef.1989.1747">Schleef RR, Higgins DL, Pillemer E, Levitt LJ. Bleeding diathesis due to decreased functional activity of type 1 plasminogen activator inhibitor. <span><span class="ref-journal">J Clin Invest. </span>1989;<span class="ref-vol">83</span>:1747–52.</span> [<a href="/pmc/articles/PMC303885/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC303885</span></a>] [<a href="/pubmed/2496147" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 2496147</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="pai-1-def.REF.zhang.2005.79">Zhang ZY, Wang ZY, Dong NZ, Bai X, Zhang W, Ruan CG. A case of deficiency of plasma plasminogen activator inhibitor-1 related to Ala15Thr mutation in its signal peptide. <span><span class="ref-journal">Blood Coagul Fibrinolysis. </span>2005;<span class="ref-vol">16</span>:79–84.</span> [<a href="/pubmed/15650551" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15650551</span></a>]</div></li></ul></div></div><div id="pai-1-def.Chapter_Notes"><h2 id="_pai-1-def_Chapter_Notes_">Chapter Notes</h2><div id="pai-1-def.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>3 August 2017 (bp) Review posted live</div></li><li class="half_rhythm"><div>30 June 2016 (mh) Original submission</div></li></ul></div></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2019, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2019 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK447152</span><span class="label">PMID: <a href="/pubmed/28771291" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">28771291</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/bethlem/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/ccfdn/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK447152&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK447152/?report=reader">PubReader</a></li><li><a href="/books/NBK447152/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK447152" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK447152" style="display:none" title="Cite this Page"><div class="bk_tt">Heiman M, Gupta S, Khan SS, et al. Complete Plasminogen Activator Inhibitor 1 Deficiency. 2017 Aug 3. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. <span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK447152/pdf/Bookshelf_NBK447152.pdf">PDF version of this page</a> (622K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this GeneReview</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#pai-1-def.Summary" ref="log$=inpage&amp;link_id=inpage">Summary</a></li><li><a href="#pai-1-def.Diagnosis" ref="log$=inpage&amp;link_id=inpage">Diagnosis</a></li><li><a href="#pai-1-def.Clinical_Characteristics" ref="log$=inpage&amp;link_id=inpage">Clinical Characteristics</a></li><li><a href="#pai-1-def.Genetically_Related_Allelic_Di" ref="log$=inpage&amp;link_id=inpage">Genetically Related (Allelic) Disorders</a></li><li><a href="#pai-1-def.Differential_Diagnosis" ref="log$=inpage&amp;link_id=inpage">Differential Diagnosis</a></li><li><a href="#pai-1-def.Management" ref="log$=inpage&amp;link_id=inpage">Management</a></li><li><a href="#pai-1-def.Genetic_Counseling" ref="log$=inpage&amp;link_id=inpage">Genetic Counseling</a></li><li><a href="#pai-1-def.Resources" ref="log$=inpage&amp;link_id=inpage">Resources</a></li><li><a href="#pai-1-def.Molecular_Genetics" ref="log$=inpage&amp;link_id=inpage">Molecular Genetics</a></li><li><a href="#pai-1-def.References" ref="log$=inpage&amp;link_id=inpage">References</a></li><li><a href="#pai-1-def.Chapter_Notes" ref="log$=inpage&amp;link_id=inpage">Chapter Notes</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>GeneReviews Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/gene/advanced/"><i>GeneReviews</i> Advanced Search</a></li><li><a href="/books/n/gene/glossary/"><i>GeneReviews</i> Glossary</a></li><li><a href="/books/n/gene/resource_mats/">Resource Materials</a> <span class="bk_hlight1">NEW FEATURE</span></li><li><a href="/books/n/gene/updates/">New in <i>GeneReviews</i></a></li><li><a href="/books/n/gene/authors/">Author List</a></li><li><a href="/books/n/gene/prospective_authors/">For Current/Prospective Authors</a></li><li><a href="/books/n/gene/GRpersonnel/"><i>GeneReviews</i> Personnel</a></li><li><a href="/books/n/gene/howto_linkin/">Download/Link to <i>GeneReviews</i></a></li><li><a href="/books/n/gene/contact_us/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Tests in GTR by Gene</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=5054[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">SERPINE1</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=omim&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_omim&amp;IdsFromResult=4431564" ref="log$=recordlinks">OMIM</a><div class="brieflinkpop offscreen_noflow">Related OMIM records</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=4431564" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=4431564" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=gene&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_gene&amp;IdsFromResult=4431564" ref="log$=recordlinks">Gene</a><div class="brieflinkpop offscreen_noflow">Locus Links</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301668" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Hemophilia B</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Hemophilia B<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Konkle BA, Huston H, Nakaya Fletcher S. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301578" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Hemophilia A</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Hemophilia A<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Konkle BA, Huston H, Nakaya Fletcher S. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301765" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> von Willebrand Disease</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> von Willebrand Disease<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Goodeve A, James P. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/24006547" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Ornithine Transcarbamylase Deficiency</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Ornithine Transcarbamylase Deficiency<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Lichter-Konecki U, Caldovic L, Morizono H, Simpson K. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301446" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Gaucher Disease</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Gaucher Disease<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Pastores GM, Hughes DA. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=28771291" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=28771291" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5dfc921975f66d18aab30e87">Complete Plasminogen Activator Inhibitor 1 Deficiency - GeneReviews®</a><div class="ralinkpop offscreen_noflow">Complete Plasminogen Activator Inhibitor 1 Deficiency - GeneReviews®<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-12-20T04:19:21-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@5.22&amp;Host=portal103&amp;ncbi_phid=CE8AF0AFDFC8A2710000000003DA01F7&amp;ncbi_session=CE8AF0AFDFC92181_0986SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK447152%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK447152&amp;ncbi_domain=gene&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK447152/&amp;ncbi_pagename=Complete Plasminogen Activator Inhibitor 1 Deficiency - GeneReviews® - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE8AF0AFDFC92181_0986SID /projects/books/PBooks@5.22 portal103 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>